# Oncimmune Holdings plc makes key appointments to further strengthen management teams

- Link: https://www.directorstalkinterviews.com/oncimmune-holdings-plc-makes-key-appointments-to-further-strengthen-management-teams/412793462
- Published: 2019-09-23T07:23:38+01:00
- Author: Giles Arbor

**Oncimmune Holdings plc** (LON: ONC), a leading global immunodiagnostics group,
has today announced the appointment of Professor Tariq Sethi as Chief Scientific
Officer, Matthew Luttrell as Chief Commercial Officer and Cléa Rosenfeld as Head
of Investor Relations.

Professor Tariq Sethi is a researcher, clinician and entrepreneur with over 35 years
of combined academic and industry experience in the field of immunology, inflammation
and Lung Cancer. Prior to joining Oncimmune, Tariq was Chief Physician Scientist,
Vice President in the Clinical Discovery Unit AstraZeneca and Emeritus Professor
of Respiratory Medicine King’s College London, having previously been Vice President
in AstraZeneca’s Respiratory Immunology Autoimmunity Translational Medicine Unit
and formally Professor of Respiratory Medicine and Lung Cancer at Edinburgh University.
He is also founder of Galecto Biotech. His research interests focus on chronic inflammatory
diseases and fibrosis and the interaction between inflammation and lung cancer. 
Given his skillset and experience Tariq is very well placed to direct and lead Oncimmune’s
discovery research, translational and clinical programmes effectively. Tariq joins
Oncimmune as from 1 October 2019 as its Chief Scientific Officer, and will also 
become part of the Senior Leadership Team.

Matthew Luttrell is a seasoned health and life science commercial executive with
experience gained in large pharmaceutical companies across HIV, Rare Diseases, Oncology
and Haematology. After starting his career in the pharmaceutical sector in 2002 
with Eli Lilly, Matthew has held senior roles in Novo Nordisk, Gilead, [GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
Shire and, most recently, Takeda. Prior to joining Oncimmune as Chief Commercial
Officer, Matthew was Head of Haematology, Growth and Emerging Markets at Shire (
now Takeda). Matthew’s extensive experience leading direct and indirect sales and
implementing commercial strategy will enhance our commercial sales capabilities 
as we seek to accelerate sales of our Early CDT products. Matthew holds a bachelor’s
degree in Biomedical Science, a master’s degree in Marketing Management as well 
as a master’s degree in Business Administration. Matthew also joins the Senior Leadership
Team at Oncimmune as from 1 October 2019.

Cléa Rosenfeld joined the Oncimmune team as Head of Investor Relations in July 2019.
Cléa is a senior investor relations and corporate communications professional with
over 15 years of experience working in [FTSE 100](https://www.directorstalkinterviews.com/news/ftse-100)
and 250 companies with global businesses and international shareholder bases. Cléa
was Head of Investor Relations at Shire Plc for 11 years, where she helped bring
the company from a [FTSE 250](https://www.directorstalkinterviews.com/news/ftse-250)
Company to a top 50 FTSE company. Her significant experience within the investor
relations community and her ability to develop and execute corporate strategy makes
her a valuable addition to our team.

**Dr Adam M Hill, Chief Executive Officer of Oncimmune Holdings commented:**

> “The appointments of Tariq, Matthew and Cléa add yet more expertise and depth 
> to our leadership teams as we establish Oncimmune as a key player in supporting
> critical clinical decisions across the cancer care pathway. I’m delighted to welcome
> them and am pleased that Oncimmune’s potential attracts such high quality, experienced
> and seasoned professionals.
> “The delivery of Oncimmune’s three-year forward strategy continues to progress
> at speed with the achievement of important milestones this year. The results of
> the landmark Scottish ECLS trial using our EarlyCDT® Lung test was presented at
> the World Conference for Lung Cancer on 9th September 2019. The trial further 
> validated the use of Oncimmune’s platform technology as a screening modality, 
> identifying cancer four years or more before standard clinical diagnosis. Our 
> strategy is one of Partnership by Design and transactions with Biodesix in the
> US and R-Pharm in Russia further demonstrate the commercial potential of Oncimmune’s
> technology platform.”

Share on:
